The estimated Net Worth of Kenneth C Frazier is at least $104 Million dollars as of 20 March 2019. Mr. Frazier owns over 192,736 units of Merck & Co stock worth over $83,098,839 and over the last 10 years he sold MRK stock worth over $0. In addition, he makes $20,934,500 as Chairman of the Board, President, and Chief Executive Officer at Merck & Co.

Mr. Frazier MRK stock SEC Form 4 insider trading

Kenneth has made over 33 trades of the Merck & Co stock since 2010, according to the Form 4 filled with the SEC. Most recently he exercised 192,736 units of MRK stock worth $7,572,597 on 20 March 2019.

The largest trade he’s ever made was exercising 392,000 units of Merck & Co stock on 5 August 2016 worth over $14,445,200. On average, Kenneth trades about 45,366 units every 49 days since 2009. As of 20 March 2019 he still owns at least 990,451 units of Merck & Co stock.

You can see the complete history of Mr. Frazier stock trades at the bottom of the page.

Kenneth Frazier biography

Kenneth C. Frazier is Chairman of the Board, President and Chief Executive Officer of the Company. Mr. Frazier previously served as Executive Vice President and President, Global Human Health of the Company (2009 to 2010) and Merck Sharp & Dohme Corp. (2007 to 2009). Mr. Frazier also served as Executive Vice President and General Counsel (2006 to 2007) of Merck Sharp & Dohme Corp. (formerly known as Merck & Co., Inc.). Director, Exxon Mobil Corporation since 2009 and Pharmaceutical Research and Manufacturers of America (PhRMA) since 2011. Trustee, The Pennsylvania State University and Cornerstone Christian Academy in Philadelphia, PA; Member, Board of Overseers of Weill Cornell Medical College and Graduate School of Medical Sciences, American Academy of Arts and Sciences, Council on Foreign Relations, the Council of the American Law Institute and the American Bar Association. Mr. Frazier has broad managerial and operational expertise and deep institutional knowledge, as well as a track record of achievement, integrity and sound judgment demonstrated prior to, and during his long tenure with Merck. In addition, his role as the Chair of the Board Affairs Committee of Exxon Mobil Corporation has provided him with important experience on governance issues facing public companies.

What is the salary of Kenneth Frazier?

As the Chairman of the Board, President, and Chief Executive Officer of Merck & Co, the total compensation of Kenneth Frazier at Merck & Co is $20,934,500. There are no executives at Merck & Co getting paid more.

How old is Kenneth Frazier?

Kenneth Frazier is 64, he’s been the Chairman of the Board, President, and Chief Executive Officer of Merck & Co since 2011. There are 7 older and 15 younger executives at Merck & Co. The oldest executive at Merck & Co., Inc. is Thomas Cech, 72, who is the Independent Director.

What’s Kenneth Frazier’s mailing address?

Kenneth’s mailing address filed with the SEC is C/O EXXON MOBIL CORPORATION, 5959 LAS COLINAS BLVD., IRVING, TX, 75039-2298.

Insider trading at Merck & Co

Over the last 10 years, insiders at Merck & Co have traded over $53,837,709 worth of Merck & Co stock and bought 47,800 units worth $1,519,400 . The most active insider traders include Wendell P Weeks, Kenneth C Frazier, and Adam H Schechter. On average, Merck & Co executives and independent directors trade stock every 15 days with the average trade being worth of $3,440,102. The most recent stock trade was executed by Steven Mizell on 30 October 2019, trading 4,574 units of MRK stock currently worth $379,276.

What does Merck & Co do?

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species, which it sells to veterinarians, distributors, and animal producers. The Healthcare Services segment offers services and solutions that focus on engagement, health analytics, and clinical services to improve the value of care delivered to patients. The Alliances segment includes results from the Company’s relationship with AstraZeneca LP related to sales of Nexium and Prilosec. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

What does Merck & Co’s logo look like?

Complete history of Mr. Frazier stock trades at Exxon Mobil and Merck & Co

Merck & Co executives and stock owners

Merck & Co executives and other stock owners filed with the SEC include:

• Kenneth Frazier, Chairman of the Board, President, Chief Executive Officer
• Roger Perlmutter, Executive Vice President, President – Merck Research Laboratories
• Robert Davis, Executive Vice President, Global Services, Chief Financial Officer
• Jennifer Zachary, Executive Vice President, General Counsel
• Peter Wendell, Independent Director
• Wendell Weeks, Independent Director
• Rochelle Lazarus, Independent Director
• Leslie Brun, Lead Independent Director
• Paul Rothman, Independent Director
• Pamela Craig, Independent Director
• Thomas Cech, Independent Director
• Patricia Russo, Independent Director
• Thomas Glocer, Independent Director
• Inge Thulin, Independent Director
• Mary Coe, Independent Director
• Rita Karachun, Senior Vice President Finance – Global Controller
• Julie Gerberding, Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health
• Richard DeLuca, Executive Vice President, President – Merck Animal Health
• Frank Clyburn, Executive Vice President, Chief Commercial Officer
• Sanat Chattopadhyay, Executive Vice President and President – Merck Manufacturing Division
• Michael Nally, Executive Vice President, Chief Marketing Officer
• Jim Scholefield, Executive Vice President, Chief Information and Digital Officer
• Steven Mizell, Executive Vice President, Chief Human Resources Officer, Human Resources
• Craig B. Thompson, Director
• Adam H Schechter, EVP & Pres-Global Human Health
• Adele D Ambrose, V-P & Chief Com. Officer
• Clark Golestani, EVP & Chief Info Officer
• John H Noseworthy, Director
• Michael J Holston, EVP, Chief Ethics & Compl Ofcr
• Carlos E Represas, Director
• C Robert Kidder, Director
• Weir Mirian M Graddick, Exec. V-P, Human Resources
• Ashley Watson, SVP Chief Ethics & Com Officer
• James H Scholefield, EVP,Chief Info&Digital Officer
• Michael Fleming, SVP Chief Ethics & Com Officer
• William B Jr Harrison, Director
• Michael Rosenblatt, Exec V-P & Chief Med Officer
• John Canan, Senior V-P, Controller
• Stanley F Barshay, Exec V-P Consumer Health Care
• Willie A Deese, Exec. V-P and Pres., MMD
• Anne M Tatlock, Director
• Samuel O Md Thier, Director
• Mervyn Turner, Chief Strategy Officer
• Willam N Kelley, Director
• Richard S Iii Bowles, Exe V-P & Chief Compl Officer
• Peter S Kim, Exec. V-P and Pres., MRL
• Thomas E Shenk, Director
• Bridgette P Heller, Exe.VP & Pres.Con.Hlth.Care
• Raul E Kohan, Exe V-P & Pres, Animal Health
• Steven F Goldstone, Director
• Harry R Jacobson, Director
• Richard T Clark, Chairman, President and CEO
• Peter N Kellogg, Exec. V.P. & C.F.O
• Bruce N Kuhlik, Exec. V.P. and General Counsel
• Cuong V Do, EVP & Chief Strategy Officer
• J Chris Scalet, Exe. VP, Global Services & CIO